---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-323850"
form_type: "8-K"
ticker: "SYBX"
cik: "0001527599"
company_name: "SYNLOGIC, INC."
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T10:39:50.182926+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Synlogic and Ginkgo announce clinical candidate SYNB1353 for homocystinuria; IND filing expected 2022

## Summary
- SYNB1353 is an investigational Synthetic Biotic medicine for homocystinuria (HCU), developed using Synlogic's platform and Ginkgo's codebase.
- First candidate from Synlogic-Ginkgo collaboration to enter IND-enabling studies.
- Synlogic expects to file an IND with FDA and begin clinical development in 2022.
- Preclinical data to be presented at International Congress of Inborn Errors of Metabolism 2021 (Nov 21-23).

## SEC filing metadata
- accession: 0001193125-21-323850
- form_type: 8-K
- ticker: SYBX
- cik: 0001527599
- company_name: SYNLOGIC, INC.
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527599/000119312521323850/0001193125-21-323850-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527599/000119312521323850/d232569d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-323850
- JSON: https://secwatch.observer/filing/0001193125-21-323850.json
- Plain text: https://secwatch.observer/filing/0001193125-21-323850.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.